CoChat

A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing

Open access

Published version of a preprint

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Abstract

We developed a screening assay in which luciferized ID8 expressing OVA was cocultured with transgenic CD8+ T cells specifically recognizing the model antigen in an H-2b–restricted manner. The assay was screened with a small-molecule library to identify compounds that inhibit or enhance T cell–mediated killing of tumor cells. Erlotinib, an EGFR inhibitor, was the top compound that enhanced T-cell killing of tumor cells. Subsequent experiments with erlotinib and additional EGFR inhibitors validated the screen results. EGFR inhibitors increased both basal and IFNγ-induced MHC class-I presentation, which enhanced recognition and lysis of tumor cell targets by CD8+ cytotoxic T lymphocytes. The ID8 cell line was also transduced to constitutively express Cas9, and a pooled CRISPR screen, utilizing the same target tumor cell/T-cell assay, identified single-guide (sg)RNAs targeting EGFR that sensitized tumor cells to T cell–mediated killing. Combination of PD-1 blockade with EGFR inhibition showed significant synergistic efficacy in a syngeneic model, further validating EGFR inhibitors as immunomodulatory agents that enhance checkpoint blockade. This assay can be screened in high-throughput with small-molecule libraries and genome-wide CRISPR/Cas9 libraries to identify both compounds and target genes, respectively, that enhance or inhibit T-cell recognition and killing of tumor cells. Retrospective analyses of squamous-cell head and neck cancer (SCCHN) patients treated with the combination of afatinib and pembrolizumab demonstrated a rate of clinical activity exceeding that of each single agent. Prospective clinical trials evaluating the combination of an EGFR inhibitor and PD-1 blockade should be conducted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-18-0193

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 92

Metadata

Authors
Lizotte, P. H., Hong, R.-L., Luster, T. A., Cavanaugh, M. E., Taus, L. J., Wang, S., Dhaneshwar, A., Mayman, N., Yang, A., Kulkarni, M., Badalucco, L., Fitzpatrick, E., Kao, H.-F., Kuraguchi, M., Bittinger, M., Kirschmeier, P. T., Gray, N. S., Barbie, D. A., & Jänne, P. A.
Affiliations
  • Dana-Farber Cancer Institute (US)
  • National Taiwan University Hospital (TW)
  • Harvard University (US)
  • 1Belfer Center for Applied Cancer Science, Boston, Massachusetts.
Venue
Cancer Immunology Research
Published
2018-12-01
Volume
6
Issue
12
Pages
1511-1523
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2891460256
Cited by
88
References
43
Citations by year
2026: 4 · 2025: 12 · 2024: 12 · 2023: 12 · 2022: 15 · 2021: 12 · 2020: 12 · 2019: 9
FWCI
3.10
Type
journal article
Language
en
Open access
Locations
  • Cancer Immunology Research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • American Cancer Society (ACS) (CRP-17-111-01-CDD)
  • Foundation for the National Institutes of Health (FNIH) (U54 HL127365)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
EGFR inhibitors, erlotinib, immune checkpoint blockade, anti-PD-1 therapy, CD8+ T cell cytotoxicity, MHC class I antigen presentation, CRISPR-Cas9 screen, small molecule screening, combination therapy, head and neck squamous cell carcinoma, pembrolizumab, afatinib, tumor immunology
MeSH terms
Squamous Cell Carcinoma of Head and Neck, Afatinib, Animals, Antineoplastic Combined Chemotherapy Protocols, Drug Screening Assays, Antitumor, Head and Neck Neoplasms, Humans, Mice, Inbred C57BL, T-Lymphocytes, Cytotoxic, CD8-Positive T-Lymphocytes, Coculture Techniques, Cell Line, Tumor, Protein Kinase Inhibitors, Luciferases, Firefly, High-Throughput Screening Assays, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized, CRISPR-Cas Systems, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0193
The paper
Lizotte, P. H., Hong, R.-L., Luster, T. A., Cavanaugh, M. E., Taus, L. J., Wang, S., Dhaneshwar, A., Mayman, N., Yang, A., Kulkarni, M., Badalucco, L., Fitzpatrick, E., Kao, H.-F., Kuraguchi, M., Bittinger, M., Kirschmeier, P. T., Gray, N. S., Barbie, D. A., & Jänne, P. A. (2018). A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0193

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.